NK

NantKwest
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.87
-0.45
-5.41%
Closed 19:23 11/23 EST
OPEN
8.28
PREV CLOSE
8.32
HIGH
8.42
LOW
7.81
VOLUME
741.89K
TURNOVER
--
52 WEEK HIGH
15.70
52 WEEK LOW
1.139
MARKET CAP
854.62M
P/E (TTM)
-10.4919
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ImmunityBio Announces Publication Of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and
Benzinga · 22h ago
NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020. NantKwest Executive Chairman Patrick Soon-Shiong, M.D., and Chief Executive Officer Rich Adcock will participate in institutional investor meetings on Tuesday, December 1; meetings may be requested through Piper Sandler.
Business Wire · 5d ago
ImmunityBio COVID-19 vaccine shows favorable safety profile in early-stage study
Results from the low dose cohort in a Phase 1 clinical trial in 20 healthy volunteers showed no serious adverse events associated with ImmunityBio's second-generation bivalent human adenovirus COVID-19 vaccine
Seekingalpha · 11/10 12:36
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have administered their second-generation bivalent, human adenovirus (hAd5) COVID-19 vaccine candidate in a Phase 1 trial with no serious adverse events (SAE) reported in the low dose cohort, safety is ongoing for the high dose cohort. The trial, being conducted at Hoag Hospital in Newport Beach, California, enrolled 20 volunteers across two dose levels and the subject screening for the Phase I expansion cohort is ongoing.
Business Wire · 11/10 12:00
Covid-Tied Biotechs Unwind Gains After Pfizer Vaccine Data
(Bloomberg) -- Biotech companies that are chasing treatments and vaccines for Covid-19 tumbled Monday after positive news about Pfizer Inc.’s inoculation.Smaller vaccine developers such as NantKwest Inc. and Inovio Pharmaceuticals Inc. fell after study results from Covid-19 shots from Pfizer and its German partner BioNTech SE showed that they could prevent more than 90% of infections. Many of these smaller drug developers have yet to develop a successful treatment of any kind and have seen triple or even quadruple digit share gains so far this year.NantKwest slumped as much as 16%. Inovio sank as much as 15% -- the company’s Phase 2-3 vaccine study was put on a partial hold in September. Humanigen Inc., which is developing a treatment for a potentially lethal side-effect of the virus, and Sorrento Therapeutics Inc., which has been touting results for its antiviral treatment in hamsters, also fell 15% each.Vaxart Inc., which is testing an oral vaccine, tumbled as much as 20%.Moderna Inc. which, like Pfizer, is working on messenger-RNA vaccines, rallied 9.3% on the heels of Pfizer’s success. Novavax Inc., which is expected to start a late stage-study later this month, briefly plunged 11% premarket Monday but then rallied as much as 10% after revealing its vaccine received fast track status in the U.S.(Updates shares throughout)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 11/09 15:02
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
ImmunityBio, Inc. a privately-held, clinical-stage immunotherapy company, today announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which shows memory T-cell recall from patients previously infected with SARS-CoV-2 virus. The ability to stimulate SARS-CoV 2 specific T-cells, which recognize the N and S proteins, is a crucial part of the novel design of ImmunityBio’s vaccine candidate. The antibody- and T cell-based vaccine seeks both to provide protection for the uninfected population and also the potential to clear virally infected cells in infected subjects. It is unclear how long antibodies may provide protection. With the production of both antibodies and T cells, the potential exists for long-term, durable immunity. The results of this study were published in medRxiv ("Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2").
Business Wire · 11/09 14:00
NantKwest Names Richard Adcock Chief Executive Officer
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven operational skills Richard Adcock as its Chief Executive Officer, effective immediately. Adcock brings extensive leadership experience to NantKwest as the company advances rapidly in the development of natural killer cell-based immunotherapies for cancer and serious infectious diseases. Rich will assume the role of CEO from Dr. Patrick Soon-Shiong, who will become Executive Chairman of the Board. Dr. Soon-Shiong remains the largest shareholder in NantKwest.
Business Wire · 10/26 21:15
NantKwest names new CEO
NantKwest (NK) appointed healthcare industry veteran Richard Adcock as its CEO, effective immediately.Richard will assume the role of CEO from Dr. Patrick Soon-Shiong, who will become the board's executive chairman; Dr. Soon-Shiong remains
Seekingalpha · 10/26 20:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NK. Analyze the recent business situations of NantKwest through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NK stock price target is 13.00 with a high estimate of 18.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 135
Institutional Holdings: 10.86M
% Owned: 10.00%
Shares Outstanding: 108.59M
TypeInstitutionsShares
Increased
29
496.52K
New
42
289
Decreased
20
851.06K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Executive Director
Patrick Soon-Shiong
President/Chief Administrative Officer/Director
Barry Simon
Chief Executive Officer
Richard Adcock
Chief Financial Officer
Sonja Nelson
Lead Director/Independent Director
Frederick Driscoll
Director
Cheryl Cohen
Independent Director
Michael Blaszyk
Independent Director
John Thomas
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NK
NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Nantkwest Inc stock information, including NASDAQ:NK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NK stock methods without spending real money on the virtual paper trading platform.